Effect of γ-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene

Journal of the National Cancer Institute

Volumn 97, Issue 21, 2005, Pages 1611-1615

  Menendez, Javier A ^a,b   Vellon, Luciano ^a,b   Colomer, Ramon ^c   Lupu, Ruth ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA LINOLENIC ACID; HERBACEOUS AGENT; POLYUNSATURATED FATTY ACID; TRANSCRIPTION FACTOR PEA3; TRASTUZUMAB;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; COLONY FORMATION; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENTIATION; EXPERIMENTATION; FLOW CYTOMETRY; GASTROINTESTINAL TUMOR; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; TUMOR GROWTH;

ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; GAMMA-LINOLENIC ACID; GASTROINTESTINAL NEOPLASMS; GENES, ERBB-2; HUMANS; IMMUNOBLOTTING; NEOPLASMS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 27944457982     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dji343     Document Type: Article

References (47)

1. Horrobin DF. Unsaturated lipids and cancer. In: Horrobin DF, editor. New approaches to cancer treatment. Edinburgh (Scotland): Churchill; 1994. p. 1-29.
2. Das UN. Gamma-linolenic acid, arachidonic acid, and eicosapentaenoic acid as potential anticancer drugs. Nutrition 1990;6:429-34.
3. Jiang WG, Bryce RP, Horrobin DF. Essential fatty acids: Molecular and cellular basis of their anti-cancer action and clinical implications. Crit Rev Oncol Hematol 1998;27:179-209.
4. Begin ME, Ells G, Das UN, Horrobin DF. Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids. J Natl Cancer Inst 1986;77:1053-62.
5. Begin ME, Ells G, Horrobin DF. Polyunsaturated fatty acid-induced cytotoxicity against tumor cells and its relationship to lipid peroxidation. J Natl Cancer Inst 1988;80:188-94.
6. Menendez JA, del Mar Barbacid M, Montero S, Sevilla E, Escrich E, Solanas M, et al. Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. Eur J Cancer 2001;37:402-13.
7. Menendez JA, Ropero S, del Barbacid MM, Montero S, Solanas M, Escrich E, et al. Synergistic interaction between vinorelbine and gamma-linolenic acid in breast cancer cells. Breast Cancer Res Treat 2002;72:203-19.
8. Menendez JA, Ropero S, Lupu R, Colomer R. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3N-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells. Oncol Rep 2004;11:1241-52.
9. Menendez JA, Colomer R, Lupu R. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3N-6) is a selective estrogen-response modulator in human breast cancer cells: Gamma-linolenic acid antagonizes estrogen receptor-dependent transcriptional activity, transcriptionally represses estrogen receptor expression and synergistically enhances tamoxifen and ICI 182,780 (Faslodex) efficacy in human breast cancer cells. Int J Cancer 2004;109:949-54.
10. Kenny FS, Pinder SE, Ellis IO, Gee JM, Nicholson RI, Bryce RP, et al. Gamma linolenic acid with tamoxifen as primary therapy in breast cancer. Int J Cancer 2000;85:643-48.
11. van der Merwe CF, Booyens J, Joubert HF, van der Merwe CA. The effect of gamma-linolenic acid, an in vitro cytostatic substance contained in evening primrose oil, on primary liver cancer: A double-blind placebo controlled trial. Prostaglandins Leukot Essent Fatty Acids 1990;40:199-202.
12. Fearon KC, Falconer JS, Ross JA, Carter DC, Hunter JO, Reynolds PD, et al. An open-label phase I/II dose escalation study of the treatment of pancreatic cancer using lithium gammalinolenate. Anticancer Res 1996;16:867-74.
13. Harris NM, Crook TJ, Dyer JP, Solomon LZ, Bass P, Cooper AJ, Birch BR. Intravesical meglumine gamma-linolenic acid in superficial bladder cancer: An efficacy study. Eur Urol 2002;42:39-42.
14. Harris NM, Anderson WR, Lwaleed BA, Cooper AJ, Birch BR, Solomon LZ. Epirubicin and meglumine gamma-linolenic acid: A logical choice of combination therapy for patients with superficial bladder carcinoma. Cancer 2003;97:71-8.
15. Das UN. Occlusion of infusion vessels on gamma-linolenic acid infusion. Prostaglandins Leukot Essent Fatty Acids 2004;70:23-32.
16. Menendez JA, Ropero S, Lupu R, Colomer R. Dietary fatty acids regulate the activation status of Her-2/neu (c-erbB-2) oncogene in breast cancer cells. Ann Oncol 2004;15:1719-21.
17. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
18. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
19. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001;61 Suppl 2:1-13.
20. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-68.
21. Xu R, Perle MA, Inghirami G, Chan W, Delgado Y, Feiner H. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 2002;15:116-24.
22. Hoque A, Sneige N, Sahin AA, Menter DG, Bacus JW, Hortobagyi GN, et al. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 2002;11:587-90.
23. Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 1997;57:1199-205.
24. Eccles SA. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 2001;6: 393-406.
25. Chen X, Yeung TK, Wang Z. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res Common 2000;277:757-63.
26. Orr MS, O'Connor PM, Kohn KW. Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells. J Natl Cancer Inst 2000;92:987-94.
27. Nelson NJ. Can HER2 status predict response to cancer therapy? J Natl Cancer Inst. 2000;92:366-67.
28. Valagussa P. HER2 status: A statistician's view. Ann Oncol 2001;12 Suppl 1:S29-S34.
29. Yamauchi H, Stearns V, Hayes DF. The role of c-erbB-2 as a predictive factor in breast cancer. Breast Cancer 2001;8:171-83.
30. Yu D, Hung MC. Role of erbB2 in breast cancer chemosensitivity. Bioessays 2000;22: 673-80.
31. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000;19:6115-21.
32. Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 2001;8:191-95.
33. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-47.
34. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002;62:4132-41.
35. Kraus MH, Popescu NC, Amsbaugh SC, King CR. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 1987;6:605-10.
36. Xing X, Wang SC, Xia W, Zou Y, Shao R, Kwong KY, et al. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med 2000;6:189-95.
37. Wang SC, Hung MC. Transcriptional targeting of the HER-2/neu oncogene. Drugs Today (Barc). 2000;36:835-43.
38. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 2004; 101:10715-20.
39. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89:4285-9.
40. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-26.
41. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
42. Bosher JM, Williams T, Hurst HC. The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc Natl Acad Sci USA 1995;92:744-7.
43. Bosher JM, Totty NF, Hsuan JJ, Williams T, Hurst HC. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene 1996;13:1701-7.
44. Hurst HC. Update on HER-2 as a target for cancer therapy: The ERBB2 promoter and its exploitation for cancer treatment. Breast Cancer Res 2001;3:395-8.
45. Vernimmen D, Gueders M, Pisvin S, Delvenne P, Winkler R. Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. Br J Cancer 2003;89:899-906.
46. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93:1852-7.
47. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27.